Matthew Steven Davids, M.D.
This page shows the publications co-authored by Matthew Davids and Stephen Chong.
Breaking through BCL-2 inhibition in CLL. Blood. 2020 03 05; 135(10):709-711.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Jun 24; 137(25):3495-3506.
Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 08 01; 106(8):2251-2256.
The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021 09; 45:102032.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.